| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OPRL1 |
| Uniprot No | P41146 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 0 |
| 活性数据 | MEPLFPAPFWEVIYGSHLQGNLSLLSPNHSLLPPHLLLNASHGAFLPLGLKVTIVGLYLAVCVGGLLGNCLVMYVILRHTKMKTATNIYIFNLALADTLVLLTLPFQGTDILLGFWPFGNALCKTVIAIDYYNMFTSTFTLTAMSVDRYVAICHPIRALDVRTSSKAQAVNVAIWALASVVGVPVAIMGSAQVEDEEIECLVEIPTPQDYWGPVFAICIFLFSFIVPVLVISVCYSLMIRRLRGVRLLSGSREKDRNLRRITRLVLVVVAVFVGCWTPVQVFVLAQGLGVQPSSETAVAILRFCTALGYVNSCLNPILYAFLDENFKACFRKFCCASALRRDVQVSDRVRSIAKDVALACKTSETVPRPA |
| 分子量 | 40.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人OPRL1(NOP受体)蛋白的3篇参考文献示例(内容基于学术背景总结，实际文献需通过数据库核实)：
---
1. **文献名称**：*Expression and Purification of Recombinant Human NOP Receptor (OPRL1) in Insect Cells for Structural Studies*
**作者**：Zhang, Y., & Roth, B. L.
**摘要**：报道了人源OPRL1蛋白在昆虫细胞系统中的重组表达与纯化方法，利用杆状病毒载体实现高效膜蛋白生产，并通过结晶筛选获得受体胞外域的初步结构信息。
2. **文献名称**：*Functional Characterization of Recombinant OPRL1: Insights into Nociceptin Signaling Pathways*
**作者**：Calò, G., Guerrini, R., & Lambert, D. G.
**摘要**：通过重组表达的OPRL1蛋白，研究了内源性配体痛敏肽(nociceptin)激活受体后的下游信号机制，包括G蛋白偶联偏好性(Gi/o)及β-arrestin招募特性，为开发靶向NOP的药物提供依据。
3. **文献名称**：*Development of a Fluorescent Ligand Binding Assay for OPRL1 Using Recombinant HEK293 Cell Membranes*
**作者**：Schulz, S., & Schröder, H.
**摘要**：构建了稳定表达重组人OPRL1的HEK293细胞系，建立了基于荧光标记配体的受体结合实验平台，用于高通量筛选小分子激动剂/拮抗剂并评估其亲和力。
---
*注：以上文献信息为模拟示例，具体研究请通过PubMed或SciFinder检索真实文献。OPRL1相关研究多集中于其疼痛调节、焦虑相关药理学作用及结构生物学领域。*
The opioid receptor-like 1 (OPRL1), also known as the nociceptin/orphanin FQ (N/OFQ) receptor, is a G protein-coupled receptor (GPCR) that binds the neuropeptide nociceptin. Identified in 1994 through homology screening with opioid receptors, OPRL1 shares approximately 60% sequence similarity with classical opioid receptors but exhibits distinct ligand specificity and functional roles. It is widely expressed in the central nervous system, particularly in regions involved in pain modulation, stress responses, and emotional processing, such as the amygdala, hippocampus, and periaqueductal gray. Unlike traditional opioid receptors, OPRL1 activation generally counteracts opioid-induced analgesia and modulates diverse physiological processes, including anxiety, reward pathways, and inflammation.
Recombinant OPRL1 protein is produced using biotechnological systems, such as Escherichia coli, yeast, or mammalian cell lines (e.g., CHO or HEK293), by inserting the human OPRL1 gene into expression vectors. The purified protein retains its native structure and ligand-binding properties, enabling studies on receptor-ligand interactions, intracellular signaling (e.g., Gi/o protein coupling, cAMP inhibition), and structural biology. It serves as a critical tool for drug discovery, particularly for developing analgesics, anxiolytics, and treatments for addiction. Research using recombinant OPRL1 has clarified its role in neuropsychiatric disorders and highlighted its therapeutic potential in conditions where traditional opioids pose risks of tolerance or dependence.
×
